4-羟基-1-苯基环己烷-1-腈 | 16541-74-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-羟基-1-苯基环己烷-1-腈
• 英文名称: 4-hydroxy-1-phenylcyclohexanecarbonitrile
• 英文别名: 4-cyano-4-phenylcyclohexanol；4-Hydroxy-1-phenylcyclohexane-1-carbonitrile
• CAS: 16541-74-5
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: FJDFZHPXHLERAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-羟基-1-苯基环己烷-1-腈 在 titanium(IV) isopropylate 、 盐酸 、 4-二甲氨基吡啶 、 三氟化硼乙醚 、 sodium methylate 、 sodium hydride 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙醚 、 异丁酰胺 、 水 、 异丙醇 、 mineral oil 为溶剂， 反应 85.0h， 生成 cis-6-[4-(1-amino-cyclopropyl)-4-phenyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one hydrochloride
  参考文献：
  名称：

  [EN] SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS
  [FR] ISOQUINOLINES ET ISOQUINOLINONES SUBSTITUÉES UTILISÉES COMME INHIBITEURS DE RHO-KINASE

  摘要：

  该发明涉及用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶磷酸化相关疾病的配方(I)的取代异喹啉和异喹啉酮，以及含有这种化合物的组合物。

  公开号：

  WO2009156100A1
• 作为产物：
  描述：

  4-氰-4-苯基环己酮 在 sodium borohydrid 作用下， 以 甲醇 为溶剂， 以3.76 g (74%)的产率得到4-羟基-1-苯基环己烷-1-腈
  参考文献：
  名称：

  Urea, thiourea and guanidine compounds and their use as anti-viral agents

  摘要：

  本发明提供了一种通过抑制病毒与宿主细胞融合来抑制包膜病毒的化合物。该病毒可以在感染细胞、易感染细胞或需要治疗的哺乳动物中被抑制。

  公开号：

  EP0806205A3

文献信息

• Urea, thiourea and guanidine compounds and their use as anti-viral agents
  申请人：ELI LILLY AND COMPANY

  公开号：EP0806205A3

  公开（公告）日：1997-11-19

  The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.

  本发明提供了一种通过抑制病毒与宿主细胞融合来抑制包膜病毒的化合物。该病毒可以在感染细胞、易感染细胞或需要治疗的哺乳动物中被抑制。
• Benzospiran derivatives
  申请人：The Upjohn Company

  公开号：US03932425A1

  公开（公告）日：1976-01-13

  This invention relates to novel benzospiran derivatives embraced by the formula ##SPC1## Wherein the sum of A and B is at least the integer 2; A is selected from the group consisting of --(CH.sub.2).sub.n -- wherein n is 1 through 5 and --(C.sub.n H.sub.2n --.sub.2 XY)-- wherein X is selected from the group consisting of hydroxy, acetoxy, amino and acetamido and Y is hydrogen, and X when taken together with Y is selected from the group consisting of =O and =CR.sup.3 R.sup.4 wherein R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen and lower alkyl of 1 through 3 carbon atoms; B is absent or --(CH.sub.2).sub.n -- wherein n is 1 through 3; R.sup.1 is selected from the group consisting of hydrogen and lower alkyl of 1 through 3 carbon atoms; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl of 1 through 3 carbon atoms, ##EQU1## WHEREIN N IS 2 THROUGH 5 AND Ar is phenyl having zero through three substituents selected from the group consisting of lower alkyl of 1 through 3 carbon atoms, lower alkoxy of 1 through 3 carbon atoms, bromine, chlorine and fluorine; R.sup.1 and R.sup.2 taken together with --N< is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, and hexamethylenimino; Z is selected from the group consisting of hydrogen, lower alkyl of 1 through 3 carbon atoms, lower alkoxy of 1 through 3 carbon atoms, nitro, amino, monoalkylamino of 1 through 3 carbon atoms, acylamido of 1 through 4 carbon atoms, bromine, chlorine and fluorine; and a pharmacologically acceptable acid addition salt thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (1) and novel derivatives thereof. The administration to humans and animals of the novel compounds (1) depresses their central nervous systems and lowers their blood pressures.

  这项发明涉及新型苯并螺环衍生物，其结构式为： 其中A和B的总和至少为整数2；A选自--(CH2)n--（其中n为1至5）和--(CnH2n--2XY)--（其中X选自羟基、乙酰氧基、氨基和乙酰胺基，Y为氢，X与Y一起时选自=O和=CR3R4，其中R3和R4选自氢和1至3个碳原子的低烷基）；B为空或--(CH2)n--（其中n为1至3）；R1选自氢和1至3个碳原子的低烷基；R2选自氢、1至3个碳原子的低烷基、 其中N为2至5，Ar为苯基，其取自0至3个取代基，选自1至3个碳原子的低烷基、1至3个碳原子的低烷氧基、溴、氯和氟；R1和R2与--N<一起是饱和杂环氨基基，选自未取代和取代的吡咯烷、哌咪啉和己亚甲基氨基；Z选自氢、1至3个碳原子的低烷基、1至3个碳原子的低烷氧基、硝基、1至3个碳原子的单烷基氨基、1至4个碳原子的酰胺基、溴、氯和氟；以及其药理学上可接受的酸盐。它还涉及上述新化合物（1）及其新衍生物的中间体和制备过程。将这些新化合物（1）用于人类和动物可抑制其中枢神经系统并降低血压。
• Organic compounds
  申请人：The Upjohn Company

  公开号：US04010201A1

  公开（公告）日：1977-03-01

  This invention relates to novel benzospiran derivatives embraced by the formula ##STR1## wherein the sum of A and B is at least the integer 2; A is selected from the group consisting of --(CH.sub.2).sub.n wherein n is 1 through 5 and --(CH.sub.n H.sub.2n --.sub.2 XY)-- wherein X is selected from the group consisting of hydroxy, acetoxy, amino and acetamido and Y is hydrogen, and X when taken together with Y is selected from the group consisting of =O and =CR.sup.3 R.sup.4 wherein R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen and lower alkyl of 1 through 3 carbon atoms; B is absent or --(CH.sub.2).sub.n wherein n is 1 through 3; R.sup.1 is selected from the group consisting of hydrogen and lower alkyl of 1 through 3 carbon atoms; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl of 1 through 3 carbon atoms, ##STR2## WHEREIN N IS 2 THROUGH 5 AND Ar is phenyl having zero through three substituents selected from the group consisting of lower alkyl of 1 through 3 carbon atoms, lower alkoxy of 1 through 3 carbon atoms, bromine, chlorine and fluorine; R.sup.1 and R.sup.2 taken together with --N< is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, and hexamethylenimino; Z is selected from the group consisting of hydrogen, lower alkyl of 1 through 3 carbon atoms, lower alkoxy of 1 through 3 carbon atoms, nitro, amino, monoalkylamino of 1 through 3 carbon atoms, acylamido of 1 through 4 carbon atoms, bromine, chlorine and fluorine; and a pharmacologically acceptable acid addition salt thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (1) and novel derivatives thereof. The administration to humans and animals of the novel compounds (1) depresses their central nervous systems and lowers their blood pressures.

  本发明涉及由以下式子包含的新的苯并吡喃衍生物：## STR1 ## 其中A和B的和至少为整数2；A从以下组中选择：--（CH.sub.2）.sub.n，其中n为1到5，和--（CH.sub.n H.sub.2n --.sub.2 XY）--，其中X从羟基，乙酰氧基，氨基和乙酰胺基组成的群体中选择，Y是氢，当X与Y一起时，从=O和=CR.sup.3 R.sup.4组成的群体中选择，其中R.sup.3和R.sup.4从氢和1到3个碳原子的低烷基组成；B不存在或为--（CH.sub.2）.sub.n，其中n为1到3；R.sup.1从1到3个碳原子的低烷基和氢中选择；R.sup.2从1到3个碳原子的低烷基，## STR2 ## 其中N为2到5，Ar为苯，其零到三个取代基从1到3个碳原子的低烷基，1到3个碳原子的低烷氧基，溴，氯和氟中选择；R.sup.1和R.sup.2与--N <一起选择来自未取代和取代的吡咯烷基，哌嗪基和六亚甲基胺基的饱和杂环氨基基团；Z从1到3个碳原子的低烷基，1到3个碳原子的低烷氧基，硝基，1到3个碳原子的单烷基氨基，1到4个碳原子的酰胺基，溴，氯和氟中选择；以及其药理学可接受的酸盐。本发明还涉及上述新化合物（1）及其新衍生物的中间体和制备方法。将新化合物（1）用于人类和动物可以抑制其中枢神经系统并降低其血压。
• SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS
  申请人：Plettenburg Oliver

  公开号：US20110190341A1

  公开（公告）日：2011-08-04

  The invention relates to substituted isoquinoline and isoquinolinones of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  本发明涉及公式（I）的取代异喹啉和异喹啉酮，用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶的磷酸化相关的疾病，以及含有这些化合物的组合物。
• ORGANIC COMPOUNDS
  申请人：Bäschlin Daniel Kaspar

  公开号：US20130012485A1

  公开（公告）日：2013-01-10

  Compounds of the formula (I) are provided: wherein V, W, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 and m are as defined in the specification; and pharmaceutically acceptable salts and prodrugs thereof. The compounds may be useful in the treatment or prevention of various diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.

  提供了化学式（I）的化合物： 其中V、W、X、Y、Z、R3、R4、R5、R6、R7和m的定义如规范中所述；以及其药学上可接受的盐和前药。这些化合物可能在治疗或预防各种与二肽基肽酶-IV（DPP-IV）有关的疾病和病况中有用。